Volker J. Schettler (Germany)
Centre of Nephrology Apheresis and DialysosAuthor Of 2 Presentations
Live Q&A (ID 1551)
O059 - The German Lipoprotein Apheresis Registry (GLAR) – more than 7 years on (ID 1468)
Abstract
Background and Aims
In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 7 years now
Methods
During the time period 2012-2020, 82 German apheresis centers collected data of 2055 patients undergoing regular lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from progressive atherosclerotic cardiovascular disease (ASCVD). A total of more than 47,000 LA treatment data were collected.
Results
All LA patients (n=930) showed an acute median reduction rate of 68.2% for LDL-C, and of 72.4% for Lp(a). Analogous to the Pro(a)LiFe pattern, incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y-1) and prospectively seven years on LA treatment (y + 1 to y + 7) were analyzed. During the first two years of LA treatment (y+1 and y+2) a MACE reduction of 78% was observed and remained low prospectively (y+3 to y+7). LA patients with only increased Lp(a) levels (Lp(a) > 60 mg/dl (> 120 nmol/l); LDL-C < 100 mg/dl (< 2.6 mmol/l)) had a higher MACE reduction (84%; n=434) in the first two years of LA treatment compared to LA patients with only increased LDL-C-levels (LDL-C > 100 mg/dl (> 2.6 mmol/l); Lp(a) < 60 mg/dl (< 120 nmol/l)) (72%; n=175).
Conclusions
The data generated by the GLAR show that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp (a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication. The results are unique.
Presenter of 2 Presentations
Live Q&A (ID 1551)
O059 - The German Lipoprotein Apheresis Registry (GLAR) – more than 7 years on (ID 1468)
Abstract
Background and Aims
In 2011 the German Lipoprotein Apheresis Registry (GLAR) was launched and data are available over nearly 7 years now
Methods
During the time period 2012-2020, 82 German apheresis centers collected data of 2055 patients undergoing regular lipoprotein apheresis (LA) treatment of high LDL-C levels and/or high Lp (a) levels suffering from progressive atherosclerotic cardiovascular disease (ASCVD). A total of more than 47,000 LA treatment data were collected.
Results
All LA patients (n=930) showed an acute median reduction rate of 68.2% for LDL-C, and of 72.4% for Lp(a). Analogous to the Pro(a)LiFe pattern, incidence rate of major coronary events (MACE) 1 and 2 years before the beginning of LA treatment (y-2 and y-1) and prospectively seven years on LA treatment (y + 1 to y + 7) were analyzed. During the first two years of LA treatment (y+1 and y+2) a MACE reduction of 78% was observed and remained low prospectively (y+3 to y+7). LA patients with only increased Lp(a) levels (Lp(a) > 60 mg/dl (> 120 nmol/l); LDL-C < 100 mg/dl (< 2.6 mmol/l)) had a higher MACE reduction (84%; n=434) in the first two years of LA treatment compared to LA patients with only increased LDL-C-levels (LDL-C > 100 mg/dl (> 2.6 mmol/l); Lp(a) < 60 mg/dl (< 120 nmol/l)) (72%; n=175).
Conclusions
The data generated by the GLAR show that LA lowers the incidence rate of cardiovascular events in patients with high LDL-C and/or high Lp (a) levels, progressive ASCVD, and maximally tolerated lipid lowering medication. The results are unique.